Drug intelligence / Profile preview

GM-CSF + procarbazine + lomustine + vincristine + T cell infusion

Development stage
Unknown
Lead developer
Partner Therapeutics
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Cell Therapies
Administration
Intravenous, Oral, Subcutaneous
01

Overview

A combination immunochemotherapy regimen that includes GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor), three chemotherapeutic agents (procarbazine, lomustine, vincristine), and T cell infusion. GM-CSF stimulates the production and function of granulocytes and macrophages, activates dendritic cells, and enhances antigen presentation to promote anti-tumor immune responses. The chemotherapy components provide direct cytotoxic effects against cancer cells, while the T cell infusion delivers additional tumor-specific immune responses. This combination aims to create synergistic effects between direct cytotoxicity and enhanced immune-mediated tumor destruction.

02

Targets

TUBB (Tubulin (alpha and beta subunits))CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)DNA

Beyond the preview

Go deeper on GM-CSF + procarbazine + lomustine + vincristine + T cell infusion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM-CSF + procarbazine + lomustine + vincristine + T cell infusion.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call